Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study

NCT03117335 is registered in ClinicalTrials.gov with Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. as lead sponsor.

NCT NCT03117335
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03117335 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study
Lead sponsor
Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
November 10, 2011
Completion date
January 17, 2017
Enrollment
560 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small cell lung cancer